Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
To the Editor: Dr Yusuf and colleagues1 reported a reduction in the risk of developing
diabetes during treatment with ramipril. However, examination of the data
presented in Figure 1 reveals that the cumulative risk of developing diabetes
in the placebo group at 2, 3, and 4 years of follow-up is approximately equal
to the cumulative risk in the ramipril group at 3, 4, and 4.5 years, respectively.
In other words, it appears that rather than preventing diabetes, treatment
with ramipril only delays the recognition of diabetes by about 1 year.
Shlossberg AH. Ramipril and Risk of Diabetes. JAMA. 2002;287(2):186-187. doi:10.1001/jama.287.2.186